期刊文献+

胸腺五肽多囊脂质体的制备及体外释放的考察 被引量:3

Preparation and drug release in vitro of Thymopentin multivesicular liposomes
原文传递
导出
摘要 目的制备胸腺五肽多囊脂质体,并考察其包封率和体外释放情况。方法采用复乳法制备胸腺五肽多囊脂质体,并用单因素、正交实验对处方进行优化。结果制备的胸腺五肽多囊脂质体的外观圆整均匀,形态良好,包封率为80.15%±3%。体外释放的零级动力学方程为:Y=0.536X+20.431(r2=0.9814),132 h的累积释放率为92.01%。结论复乳法制备的胸腺五肽多囊脂质体的工艺可行,包封率较高,有明显的缓释特征。 OBJECTIVE To prepare Thymopentin muhivesicular liposomes and investigate the encapsulation efficiency and drug release profile in vitro. METHODS Thymopentin multivesicular liposomes were prepared by double emulsion process, then, the formulation was optimized by single factor and orthogonal design experiments. RESULTS Thymopentin muhivesieular liposomes seemed round,well- distributed and had good appearances. The encapsulation efficiency was 80.15% ± 3%. The release kinetics was characterized by zero - order equation : Y = 0. 536X + 20.431 ( r^2 = 0.9814), and the cumulative release of multivesecular was 92.01% within 132 h. CONCLUSION It is effective to use double emulsion method, and Thymopentin muhivesecular liposomes show high encapsulation efficiencies and significant sustained release properties.
出处 《华西药学杂志》 CAS CSCD 北大核心 2009年第3期229-231,共3页 West China Journal of Pharmaceutical Sciences
关键词 胸腺五肽 多囊脂质体 包封率 体外释放 Thymopentin Multivesicular liposomes Encapsulation efficiency Drug release in vitro
  • 相关文献

参考文献3

  • 1Gonser s,Weber E,Folkers G.Peptides and polypeptides as modulatom of the immune response:thymopentin an example with unknown mode of action[J].Pharma Acta Helve,1999,73(6):265-273.
  • 2Tischio JP,Patrick JE,Weintraub HS,et al.Short in vitro halflife of Thymopoietin32-36 pentapeptide in human plasma[J].Int J Peptide Protein Res,1979,14:479-484.
  • 3Sankaram M.A lipid based depot (DepoFoam technology) for sustained release drug delivery[J].Progress in Lipid Res,2002,41:392-406.

同被引文献24

  • 1王莉,陆融,王犁明,赵琳,傅正,王松,李会强,杨海贤,章明放,金孟珏,姚智.酪丝亮肽对人肝癌BEL-7402裸鼠移植瘤的抑制作用[J].中国新药与临床杂志,2005,24(11):857-861. 被引量:6
  • 2Jian QIU,Xiao-hui WEI,Fang GENG,Rui LIU,Jing-wu ZHANG,Yu-hong XU.Multivesicular liposome formulations for the sustained delivery of interferon α-2b[J].Acta Pharmacologica Sinica,2005,26(11):1395-1401. 被引量:11
  • 3王晓梅,唐星,何海冰.多囊脂质体的研究进展[J].中国新药杂志,2006,15(15):1243-1246. 被引量:17
  • 4张宏波,项琪,赵文,黄亚东,李校堃.多肽、蛋白类药物脂质体研究进展[J].中国生物工程杂志,2007,27(6):101-106. 被引量:10
  • 5Valeria MDM. Assessment of physical and antioxidant activity stability,in vitro release and in vivo efficacy of formulations added with superoxide dismutase alone or in association, with a - toeopherol [ J ]. Euro J Pharmae Biopharmae, 2007,66 : 451 - 459.
  • 6Vladimir R. Targeting of superoxide dismutase and catalase to vascular endothelium[ J]. J Contr Rel,2001,71:1 -21.
  • 7Ozge Celik, Julide Akbuga. Preparation of superoxide dismutase loaded chitosan microspheres: Characterization and release studies[J]. Eur J Pharm Biopharma,2007,66:42 -47.
  • 8Tucker TK,Ritter AJ.Naltrexone in the treatment of heroin dependence:a literature review[J].Drug Alcohol Rev,2000,19(1):73-82.
  • 9Rossi S,Sandri G,Cararnella CM,et al.Buccal drug delivery:a challenge already won[J].Drug Discov Today,2005,2(1):59-65.
  • 10Thomas CP,Wallack SS,Lee S,et al.Research to practice:adoption of naltrexone in alcoholism treatment[J].J Subst Abuse Treat,2003,24(1):1-11.

引证文献3

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部